Navigation Links
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Date:8/5/2009

nical trials to assess the efficacy and safety of VYVANSE as adjunctive therapy in depression, for the treatment of negative symptoms and cognitive impairment in schizophrenia, and for the treatment of cognitive impairment in depression. Velaglucerase alfa - for the treatment of Gaucher disease - On July 16, 2009 Shire announced that it had received Fast Track designation from the FDA for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Gaucher disease. On July 30 Shire began the rolling submission of a NDA for velaglucerase alfa to treat patients with Type 1 Gaucher disease. Fast Track is a process which expedites the review of drugs to treat serious diseases and fill an unmet medical need with the goal of getting important new treatments to patients earlier. Shire will file additional sections of the NDA as they become available. Results from the first of the three Phase 3 trials were positive, and achieved statistically significant improvements in the primary endpoint. Velaglucerase alfa was also found to be well tolerated with no drug related serious adverse events reported in this trial. - On August 3, 2009 Shire announced that it had received approval from the FDA on the initiation of a treatment protocol for velaglucerase alfa. This protocol was submitted at the request of the FDA, in view of a potential restriction on the availability of the current approved and marketed treatment for Gaucher disease patients. This will allow physicians to treat Gaucher disease patients with velaglucerase alfa ahead of commercial availability in the US. Under the conditions of the treatment protocol, Shire will provide velaglucerase alfa free of charge initially, in order to provide access to patients as quickly as possible.

FI
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
2. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
3. Shire begins the year with a strong performance
4. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
5. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
6. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
7. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
8. Publication of Shire plcs Annual Report 2008
9. Shires Project Playground Gives Boost to Philadelphia
10. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
11. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced the ... report to their offering. , Global Market ... on Trypsin globally and regionally ( Europe , ... , Latin America etc.). It captures ... This report focuses on three primary areas; manufacture methods & ...
(Date:2/27/2015)... 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), a ... therapeutics, today announced that it will be presenting at ... March 2 nd at 3pm PST. Patrick Lucy, chief ... discussing the current state of the biosimilar industry landscape ... For more information on CALBIO 2015 and ...
(Date:2/27/2015)... 2015   PureTech , a science and technology ... products and technologies in the healthcare sector, announced today ... and Member of the Board of Directors of Sanofi, ... has been a pleasure to know Chris for many ... be working together more closely now," said Dr. ...
(Date:2/26/2015)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... and commercializes proprietary technologies and products for advanced microarray ... the fiscal first quarter ended December  31, 2014. All ... (CAD), unless otherwise stated. "During the ... our existing customers and add to our sales pipeline," ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... , , LOS ANGELES, Aug. 6 ... an 82 year-old Chinese female immigrant who suffered Stevens-Johnson Syndrome/Toxic Epidermal ... Defendant, an osteopathic physician and registered pharmacist, prescribed it to her ... did not have gout. The doctor claimed that she told ...
... , , OMAHA, Neb., Aug. 6 Transgenomic Inc. (OTC ... What: Transgenomic Inc. Second Quarter 2009 Earnings Release, ... Wednesday, August 12, 2009 @ 5:00 p.m. Eastern, Where: ... the Internet -- Simply log on to the web at the, ...
... , , , , ... drugs to combat Alzheimer,s began journey 8 years ago , , ... of a million" , , NEW YORK, Aug. 6 ... (ADDF) , have achieved a significant milestone in their development as they advance ...
Cached Biology Technology:The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict 2Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast 2PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 2PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 3
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... surrounds the DNA of our cells could help develop treatments ... have discovered that the proteins within this coating known ... different organs of the body. This variation ... proteins in the protective seal to cause illness in some ...
... Daejeon, Republic of Korea, February 26, 2013The Korea Advanced ... a global energy and petrochemicals enterprise, signed on February ... Agreement) on joint collaborations in research and development of ... Agreement was subsequently concluded upon the signing of the ...
... is faced with some of the world,s worst pollution. Until ... a major contributor to that pollution human-caused nitrogen emissions ... biology professor and Stanford Woods Institute senior fellow Peter Vitousek ... deposited on land and water in China by way of ...
Cached Biology News:Cell discovery could hold key to causes of inherited diseases 2Launched the Saudi Aramco-KAIST CO2 Management Center in Korea 2Stanford scientists help shed light on key component of China's pollution problem 2
For relative and/or absolute quantification with standard accuracy requirements using MS or NMR instruments...
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
For testing the AQUA technique on your MS instruments....
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
Biology Products: